What are the effects of SGLT2 inhibitors on serum creatinine?

Under normal circumstances, SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin, canagliflozin) may cause the following renal-related changes: a slight increase in serum creatinine, a decline in estimated glomerular filtration rate (eGFR), altered creatinine excretion efficiency, short-term fluctuations in renal function, and eventual stabilization of creatinine levels over the long term. These medications must be used under the guidance of a physician. A detailed analysis follows:

1. Mild Increase in Serum Creatinine

SGLT2 inhibitors modulate tubular reabsorption function in the kidney and alter renal hemodynamics. Specifically, they induce constriction of the afferent arteriole, reducing renal perfusion and decreasing the glomerular filtration load. As a result, creatinine in the bloodstream is not efficiently cleared by the kidneys, leading to a modest rise in serum creatinine levels.

2. Decline in Estimated Glomerular Filtration Rate (eGFR)

Changes in serum creatinine directly affect eGFR calculations. As serum creatinine rises, the calculated eGFR correspondingly decreases. This change typically occurs during the initial phase of treatment and represents an adaptive physiological response of the kidney.

3. Altered Creatinine Excretion Efficiency

SGLT2 inhibitors act on sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubules, thereby interfering with the transport of electrolytes and metabolic waste products. This leads to a slowdown in the glomerular filtration and tubular excretion of creatinine, resulting in reduced urinary creatinine excretion and mild systemic creatinine accumulation.

4. Short-Term Fluctuations in Renal Function

During the initial period of SGLT2 inhibitor therapy, the kidneys require time to adapt to drug-induced changes in hemodynamics and metabolism. Consequently, serum creatinine levels may transiently fluctuate, accompanied by temporary variations in glomerular filtration function. These effects gradually subside as the body adapts.

5. Long-Term Stabilization of Creatinine Levels

With continued administration of SGLT2 inhibitors, the kidneys progressively adapt to the drug’s mechanism of action, and renal hemodynamics stabilize. The initial rise in serum creatinine ceases, and creatinine levels plateau within a stable range. Importantly, long-term use may confer protective effects on glomerular filtration function.

In addition, renal function—including serum creatinine—should be monitored regularly during treatment. Healthcare providers may adjust the therapeutic regimen based on observed trends in these parameters to ensure safe and effective medication use.